Trial · NCT03301454
Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer
NCT03301454, Phase 2, Terminated, Centre Oscar Lambret
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer. Trials, record NCT03301454. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03301454
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer
- NCT number
- NCT03301454
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- Centre Oscar Lambret
- Conditions
- Esophageal Cancer, Squamous Cell
- Interventions
- pursuit of chemotherapy
- First posted
- 2017-10-04
- Last updated
- 2026-03-18
- Other registries' IDs
- eudract:2017-003660-13
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Estimate the overall survival for patients suffering from Esophageal cancer | From date of randomization until the date of death from any cause, up to 8 months after the beginning of the treatment | Non-progressive disease at and after 6 weeks of treatment until progression |
| Secondary | Estimate efficiency in term of overall survival, of pursuing chemotherapy | From date of randomization until the date of death from any cause, up to 8 months after the beginning of the treatment | beyond 6 weeks of treatment compared to a group that interrupted the treatment at 6 weeks |
| Secondary | Estimate the efficiency in term of progression-free of pursuing chemotherapy | From date of randomization until the date of first documented progression or date of death from any cause, up to 8 months after the beginning of the treatment | beyond 6 weeks of treatment |
| Secondary | Estimate the rate of non progressive patients | From date of inclusion until the date of the end the 6 firsts weeks of treatment | after the 6 firsts weeks of treatment |
| Secondary | Estimate the overall survival of the whole study population | From date of inclusion until the date of death from any cause, up to 8 months after the beginning of the treatment | beyond the inclusion |
| Secondary | Measure the toxicity of chemotherapy | from baseline up to 12 months | during the initial treatment phase compared to the 2 treatment arms after randomization |
| Secondary | Estimate the consequences of pursuing chemotherapy | From date of randomization until the date of first documented progression or date of death from any cause, up to 8 months after the beginning of the treatment | beyond 6 weeks of treatment in term of time until degradation of life quality and in term of overall benefits |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03301454
GET https://conductscience.org/api/trials/v1/NCT03301454/registered